137 related articles for article (PubMed ID: 26988600)
1. Single chain antibody fragments with pH dependent binding to FcRn enabled prolonged circulation of therapeutic peptide in vivo.
Qiu Y; Lv W; Xu M; Xu Y
J Control Release; 2016 May; 229():37-47. PubMed ID: 26988600
[TBL] [Abstract][Full Text] [Related]
2. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.
Borrok MJ; Wu Y; Beyaz N; Yu XQ; Oganesyan V; Dall'Acqua WF; Tsui P
J Biol Chem; 2015 Feb; 290(7):4282-90. PubMed ID: 25538249
[TBL] [Abstract][Full Text] [Related]
3. An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein.
Seijsing J; Lindborg M; Höidén-Guthenberg I; Bönisch H; Guneriusson E; Frejd FY; Abrahmsén L; Ekblad C; Löfblom J; Uhlén M; Gräslund T
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17110-5. PubMed ID: 25406323
[TBL] [Abstract][Full Text] [Related]
4. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life.
Mackness BC; Jaworski JA; Boudanova E; Park A; Valente D; Mauriac C; Pasquier O; Schmidt T; Kabiri M; Kandira A; Radošević K; Qiu H
MAbs; 2019 Oct; 11(7):1276-1288. PubMed ID: 31216930
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like Peptide 1 Conjugated to Recombinant Human Serum Albumin Variants with Modified Neonatal Fc Receptor Binding Properties. Impact on Molecular Structure and Half-Life.
Bukrinski JT; Sønderby P; Antunes F; Andersen B; Schmidt EGW; Peters GHJ; Harris P
Biochemistry; 2017 Sep; 56(36):4860-4870. PubMed ID: 28799326
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
[TBL] [Abstract][Full Text] [Related]
7. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
[TBL] [Abstract][Full Text] [Related]
8. Albumin-binding domain extends half-life of glucagon-like peptide-1.
Tan H; Su W; Zhang W; Zhang J; Sattler M; Zou P
Eur J Pharmacol; 2021 Jan; 890():173650. PubMed ID: 33049303
[TBL] [Abstract][Full Text] [Related]
9. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A
MAbs; 2015; 7(2):331-43. PubMed ID: 25658443
[TBL] [Abstract][Full Text] [Related]
10. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.
Yeung YA; Leabman MK; Marvin JS; Qiu J; Adams CW; Lien S; Starovasnik MA; Lowman HB
J Immunol; 2009 Jun; 182(12):7663-71. PubMed ID: 19494290
[TBL] [Abstract][Full Text] [Related]
11. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
[TBL] [Abstract][Full Text] [Related]
12. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
13. Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics.
Andersen JT; Cameron J; Plumridge A; Evans L; Sleep D; Sandlie I
J Biol Chem; 2013 Aug; 288(33):24277-85. PubMed ID: 23818524
[TBL] [Abstract][Full Text] [Related]
14. Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding.
Andersen JT; Dalhus B; Viuff D; Ravn BT; Gunnarsen KS; Plumridge A; Bunting K; Antunes F; Williamson R; Athwal S; Allan E; Evans L; Bjørås M; Kjærulff S; Sleep D; Sandlie I; Cameron J
J Biol Chem; 2014 May; 289(19):13492-502. PubMed ID: 24652290
[TBL] [Abstract][Full Text] [Related]
15. Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life.
Andersen JT; Foss S; Kenanova VE; Olafsen T; Leikfoss IS; Roopenian DC; Wu AM; Sandlie I
J Biol Chem; 2012 Jun; 287(27):22927-37. PubMed ID: 22570488
[TBL] [Abstract][Full Text] [Related]
16. Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn.
Yang D; Giragossian C; Castellano S; Lasaro M; Xiao H; Saraf H; Hess Kenny C; Rybina I; Huang ZF; Ahlberg J; Bigwarfe T; Myzithras M; Waltz E; Roberts S; Kroe-Barrett R; Singh S
MAbs; 2017 Oct; 9(7):1105-1117. PubMed ID: 28786732
[TBL] [Abstract][Full Text] [Related]
17. The X-Ray Crystallographic Structure of the Human Neonatal Fc Receptor at Acidic pH Gives Insights into pH-Dependent Conformational Changes.
Taha M; Ward SE; Nam HJ
Protein Pept Lett; 2016; 23(6):525-9. PubMed ID: 27041699
[TBL] [Abstract][Full Text] [Related]
18. Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Agonist, GLP-1-IgG2σ-Fc.
Yang Y; Chen F; Wan D; Liu Y; Yang L; Feng H; Cui X; Gao X; Song H
PLoS One; 2016; 11(5):e0156449. PubMed ID: 27232339
[TBL] [Abstract][Full Text] [Related]
19. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.
Schoch A; Kettenberger H; Mundigl O; Winter G; Engert J; Heinrich J; Emrich T
Proc Natl Acad Sci U S A; 2015 May; 112(19):5997-6002. PubMed ID: 25918417
[TBL] [Abstract][Full Text] [Related]
20. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.
Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A
MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
